Ovarian Cancer

New research examines the mechanisms underlying why most patients with high-grade serous ovarian cancer develop resistance to PARP inhibitors.

Researchers have developed a mouse model of high-grade serous carcinoma that could prove useful in the preclinical testing of prevention strategies for ovarian cancer.

Optical coherence tomography and multispectral fluorescence imaging have demonstrated promising results in the early detection of ovarian cancer.

Sorafenib combined with topotecan and then continued as maintenance therapy offered a significant improvement in survival outcomes in women with platinum-resistant ovarian cancer.

Apatinib combined with etoposide offers promising efficacy in patients with platinum-resistant ovarian cancer.

The regimen consisting of carboplatin and paclitaxel represents the backbone of ovarian cancer treatment. Here, we reflect on our experience administering the carboplatin/paclitaxel regimen to scores of ovarian cancer patients over the past decade and a half.

A murine study suggests this engineered combination may offer a major advantage over current CAR T-cell–based immunotherapies.

The intratumoral vasculature of high-grade serous ovarian cancer does not appear to undergo significant changes during disease progression.

Recent use of aspirin or NSAIDs is associated with improved ovarian cancer–specific survival.

The approval of PARP inhibitors has caused a paradigm shift in ovarian cancer management and a challenge for clinicians, who must decide how best to use these agents in individualized treatment.

Following diagnosis, only one-third of black women in this retrospective study were referred to genetic counselors-and none actually received counseling.

In women with ovarian cancer, those with early life adversity and anxiety had more dysregulation of cortisol, suggesting they may be at risk for more negative outcomes.

New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.

Secondary cytoreductive surgery was not associated with improvement in either OS or PFS in patients with platinum-sensitive recurrent ovarian cancer.

The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers.

The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial, ovarian, and triple-negative breast cancers.

A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone.

Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.

TPIV200 stimulates T cells to attack ovarian and triple-negative breast tumor cells that over-express the folate receptor alpha protein.

A personalized cancer vaccine was well tolerated and was capable of inducing antitumor T-cell immunity in patients with recurrent ovarian cancer.

The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

A study presented at the SGO Annual Meeting found that PARP-7 amplification mutations are associated with prolonged survival among patients with platinum-sensitive ovarian cancer.

A single-institution study of patients with advanced/recurrent EOCs found no overall survival differences for Caucasians and minorities who had participated in a clinical trial.

PARP inhibitors are offering new treatment options for ovarian cancer patients with known mutations, but early-stage diagnosis is still elusive.

A registry study suggests that there may be a familial association between ovarian and testicular cancers.

A large study found no association between the use of metformin or statins and the incidence of ovarian cancer in women with type 2 diabetes.

In this interview, Dr. Stephanie Blank discusses the recently released updates to the US Preventive Services Task Force Guideline on Ovarian Cancer Screening, and how patients and clinicians should interpret them and take action.

Intraperitoneal (IP) chemotherapy is a reasonable treatment approach for ovarian cancer because it can directly expose the surface tissues to which the cancer has disseminated to an extremely high concentration of the chemotherapy drug.

There will be no further randomized phase III trials of cytotoxic IP chemotherapy; IP therapy in ovarian cancer will soon be an historical footnote along with other failed approaches in cancer care.

Lifastuzumab vedotin offered a modest improvement in progression-free survival over standard care in patients with platinum-resistant ovarian cancer.